Jin Y. Jin

2.5k total citations
95 papers, 1.9k citations indexed

About

Jin Y. Jin is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Jin Y. Jin has authored 95 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 22 papers in Molecular Biology and 21 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jin Y. Jin's work include HER2/EGFR in Cancer Research (20 papers), Monoclonal and Polyclonal Antibodies Research (20 papers) and Statistical Methods in Clinical Trials (19 papers). Jin Y. Jin is often cited by papers focused on HER2/EGFR in Cancer Research (20 papers), Monoclonal and Polyclonal Antibodies Research (20 papers) and Statistical Methods in Clinical Trials (19 papers). Jin Y. Jin collaborates with scholars based in United States, France and Switzerland. Jin Y. Jin's co-authors include William J. Jusko, Debra C. DuBois, Richard R. Almon, Sandhya Girish, René Bruno, Nageshwar Budha, Sravanthi Cheeti, Chunze Li, Mark J. Dresser and Bert L. Lum and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Jin Y. Jin

93 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jin Y. Jin United States	24	732	538	384	210	204	95	1.9k
Chee M. Ng United States	23	481 0.7×	503 0.9×	401 1.0×	97 0.5×	239 1.2×	57	1.7k
Dinesh P. de Alwis United States	21	900 1.2×	517 1.0×	118 0.3×	165 0.8×	182 0.9×	37	1.6k
Chunze Li United States	24	649 0.9×	425 0.8×	404 1.1×	67 0.3×	147 0.7×	93	1.6k
Wojciech Krzyżański United States	27	354 0.5×	658 1.2×	317 0.8×	164 0.8×	278 1.4×	115	2.1k
Alexander Staab Germany	23	541 0.7×	445 0.8×	146 0.4×	156 0.7×	174 0.9×	54	2.0k
Ivan Nestorov United States	30	409 0.6×	463 0.9×	423 1.1×	176 0.8×	623 3.1×	88	2.5k
David Carlile United Kingdom	24	1.1k 1.5×	517 1.0×	278 0.7×	87 0.4×	266 1.3×	55	2.3k
Karin Jorga Switzerland	25	388 0.5×	382 0.7×	116 0.3×	136 0.6×	83 0.4×	48	2.0k
Ivelina Gueorguieva United States	31	1.7k 2.4×	1.4k 2.6×	130 0.3×	223 1.1×	698 3.4×	81	3.5k
Nehmé El-Hachem Canada	19	297 0.4×	892 1.7×	351 0.9×	39 0.2×	121 0.6×	50	1.9k

Countries citing papers authored by Jin Y. Jin

Since Specialization

Citations

This map shows the geographic impact of Jin Y. Jin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jin Y. Jin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jin Y. Jin more than expected).

Fields of papers citing papers by Jin Y. Jin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jin Y. Jin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jin Y. Jin. The network helps show where Jin Y. Jin may publish in the future.

Co-authorship network of co-authors of Jin Y. Jin

This figure shows the co-authorship network connecting the top 25 collaborators of Jin Y. Jin. A scholar is included among the top collaborators of Jin Y. Jin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jin Y. Jin. Jin Y. Jin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhu, Rui, Rik C. Schoemaker, Xianbin Tian, et al.. (2024). Model‐based comparisons of post‐treatment free IgE and FEV1 between omalizumab asthma dosing tables in the United States and European Union. British Journal of Clinical Pharmacology. 90(12). 3190–3200. 1 indexed citations

Marchand, Mathilde, António Gonçalves, François Mercier, et al.. (2024). Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two‐stage approaches. CPT Pharmacometrics & Systems Pharmacology. 13(6). 1017–1028. 3 indexed citations

Liu, Gengbo, et al.. (2024). Deep‐NCA: A deep learning methodology for performing noncompartmental analysis of pharmacokinetic data. CPT Pharmacometrics & Systems Pharmacology. 13(5). 870–879. 2 indexed citations

Kågedal, Matts, Mauricio Maia, Tong Lu, et al.. (2023). Population Pharmacokinetics of Ranibizumab Delivered via the Port Delivery System Implanted in the Eye in Patients with Neovascular Age‐Related Macular Degeneration. The Journal of Clinical Pharmacology. 63(11). 1210–1220. 4 indexed citations

Joshi, Amita, Saroja Ramanujan, & Jin Y. Jin. (2023). The convergence of pharmacometrics and quantitative systems pharmacology in pharmaceutical research and development. European Journal of Pharmaceutical Sciences. 182. 106380–106380. 8 indexed citations

Bruno, René, Pascal Chanu, Matts Kågedal, et al.. (2023). Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models. British Journal of Cancer. 129(9). 1383–1388. 13 indexed citations

Shemesh, Colby S., Phyllis Chan, Mathilde Marchand, et al.. (2023). Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition‐Survival Modeling Framework. Clinical Pharmacology & Therapeutics. 114(3). 644–651. 4 indexed citations

Krishnan, Sreenath M., Lena E. Friberg, François Mercier, et al.. (2023). Multistate Pharmacometric Model to Define the Impact of Second‐Line Immunotherapies on the Survival Outcome of the IMpower131 Study. Clinical Pharmacology & Therapeutics. 113(4). 851–858. 8 indexed citations

Gonçalves, António, Mathilde Marchand, Phyllis Chan, et al.. (2023). Comparison of two‐stage and joint TGI‐OS modeling using data from six atezolizumab clinical studies in patients with metastatic non‐small cell lung cancer. CPT Pharmacometrics & Systems Pharmacology. 13(1). 68–78. 4 indexed citations

10.

Schmidt, Stephan, Valvanera Vozmediano, Rodrigo Cristofoletti, et al.. (2023). Requirements, expectations, challenges and opportunities associated with training the next generation of pharmacometricians. CPT Pharmacometrics & Systems Pharmacology. 12(7). 883–888. 4 indexed citations

11.

Bruno, René, Mathilde Marchand, Kenta Yoshida, et al.. (2023). Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150. Clinical Cancer Research. 29(6). 1047–1055. 13 indexed citations

12.

Lu, Tong, et al.. (2023). gPKPDviz: A flexible R shiny tool for pharmacokinetic/pharmacodynamic simulations using mrgsolve. CPT Pharmacometrics & Systems Pharmacology. 13(3). 341–358. 2 indexed citations

13.

Goteti, Kosalaram, Mindy Magee, Sven Mensing, et al.. (2023). Opportunities and Challenges of Disease Progression Modeling in Drug Development – An IQ Perspective. Clinical Pharmacology & Therapeutics. 114(2). 266–274. 5 indexed citations

14.

Marchand, Mathilde, Rong Zhang, Phyllis Chan, et al.. (2021). Time-dependent population PK models of single-agent atezolizumab in patients with cancer. Cancer Chemotherapy and Pharmacology. 88(2). 211–221. 24 indexed citations

15.

Chan, Phyllis, Mathilde Marchand, Kenta Yoshida, et al.. (2021). Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework. CPT Pharmacometrics & Systems Pharmacology. 10(10). 1171–1182. 24 indexed citations

16.

Bruno, René, Dean Bottino, Dinesh P. de Alwis, et al.. (2019). Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models. Clinical Cancer Research. 26(8). 1787–1795. 61 indexed citations

17.

Morrissey, Kari M., Mathilde Marchand, Hina Patel, et al.. (2019). Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. Cancer Chemotherapy and Pharmacology. 84(6). 1257–1267. 62 indexed citations

18.

Claret, Laurent, Jin Y. Jin, Charles Ferté, et al.. (2018). A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics. Clinical Cancer Research. 24(14). 3292–3298. 53 indexed citations

19.

Graham, Richard, Bert L. Lum, Sravanthi Cheeti, et al.. (2011). Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding. Clinical Cancer Research. 17(8). 2512–2520. 97 indexed citations

20.

LoRusso, Patricia, Antonio Jimeno, Grace K. Dy, et al.. (2011). Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors. Clinical Cancer Research. 17(17). 5774–5782. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact